Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 8Breast Neoplasms 6Sarcoma 3Pancreatic Neoplasms 2Nasopharyngeal Carcinoma 2Colorectal Neoplasms 2Whole-Brain Radiotherapy 1Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Solid Tumors 1Solid Tumor 1Small Cell Lung Carcinoma 1Sarcoma, Synovial 1Sarcoma, Alveolar Soft Part 1Recurrence 1Pancreatic Adenocarcinoma Metastatic 1Ovarian Cancer Recurrent 1Neoplasm Metastasis 1Locally Advanced Thyroid Gland Carcinoma 1Leiomyosarcoma 1Kidney Neoplasms 1Hyperthermia 1HER2-Negative Breast Cancer 1Gallbladder Neoplasms 1Esophageal Squamous Cell Carcinoma 1Esophageal Neoplasms 1Craniopharyngioma 1Cholangiocarcinoma 1

Interventions

trifluridine tipiracil drug combination 1trametinib 1tovorafenib 1tocilizumab 1dabrafenib 1binimetinib 1anlotinib 1Surveys and Questionnaires 1Qsymia 1Phentermine 1Oxaliplatin 1Nivolumab 1Leucovorin 1Fluorouracil 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Craniopharyngioma × anlotinib × Clear all
NCT06970145 2025-11-18

Safety and Efficacy of Anlotinib in the Treatment of Recurrent Craniopharyngioma

Nanfang Hospital, Southern Medical University

Phase 1/2 Recruiting
57 enrolled
CNS

Craniopharyngioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡